Do you want to skip to content? Skip to content
Contact Us Convatec Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本
Convatec Convatec False /oidc-signin/en-us/

Most visited pages

Reports, results and presentations
Contact Us Convatec Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本

08 March 2022

Download press release

PDF Download

 

Topline momentum, profit1,2 growth and continued strategic progress

Pivoting to sustainable and profitable growth

  • Good financial performance in 2021: strong revenue growth and broadly stable constant currency margin resulting in attractive EPS growth - underpinning an inaugural dividend increase
  • Continued progress executing our FISBE (Focus, Innovate, Simplify, Build, Execute) strategy:
    • Strengthened the continence business, within CCC, through Cure Medical and Patient Care Medical acquisitions and divestment of non-core lower-margin incontinence activities
    • Revenues in our top 12 markets grew 7.9% on a constant currency1,3 basis during 2021
    • Launched innovative and differentiated Extended Wear Infusion Set in Europe, continued progress advancing our product pipeline and introduced a new and consistent product development/launch process across the Group. Invested $95 million in R&D (+15%)
    • Embedded Marketing Centre of Excellence (‘CoE’), established Quality CoE and began to leverage the benefits of Salesforce and Pricing CoEs which were established in 2020
  • Additional progress since the year-end with agreement to enter the attractive Wound Biologics4 segment with proposed acquisition of Triad Life Sciences, expected to complete in March

FY 2021 key financial highlights

table

 

  • Strong revenue growth: +7.6%, +5.8% on a constant currency3 basis and +5.3% on an organic5 basis
    • Driven by strong growth in Advanced Wound Care and Infusion Care and modest growth in Ostomy Care and CCC (comprising of good growth in the continence business moderated by stable performance in critical care products)
    • Total revenue growth supported by the Cure Medical and Patient Care Medical acquisitions partially offset by impact of non-core skin care and incontinence divestments (incremental $10 million)
  • Adjusted EBIT1,2 performance improved: +3.3% and +5.4% on a constant currency3 basis
  • Constant currency adjusted EBIT2,3 margin of 18.4% in line with guidance. Profitability reflected continued investment, foreign exchange and inflationary headwinds. Adjusted4 EBIT margin of 17.7% (2020: 18.5%). 
  • Reported operating profit was $204 million (2020: $211 million). Year on year change principally reflecting foreign exchange, continued investment, higher amortisation of acquired intangibles and acquisition and divestiture related costs. 
  • Improved earnings momentum: adjusted1 diluted EPS +8.3%. Reported diluted EPS +3.5%
  • Strengthened balance sheet: despite significant strategic investments, leverage was reduced to 1.9x net debt1/adjusted EBITDA1 (2020: 2.0x).
  • Inaugural dividend increase: Proposed final DPS of 4.154 cents to raise FY DPS by 3.0% to 5.871 cents

2022 outlook

  • For 2022, we expect to achieve sustained organic5 revenue growth of between 4.0-5.5%. Notwithstanding the inflationary backdrop we currently expect constant currency adjusted2,3 EBIT margin to increase to at least 18% compared to 17.7% in 2021.

Karim Bitar, Chief Executive Officer, commented:

“Convatec’s competitive position and financial performance continues to strengthen as we successfully execute our FISBE strategy. Our performance in 2021 demonstrates we are now pivoting to sustainable and profitable growth – with good revenue and earnings momentum. During 2021 we made significant operational improvements and grew our portfolio through strategic M&A – enabling us to deliver more effectively for our customers. I want to thank all my Convatec colleagues for their efforts over the past 12 months enabling us to deliver, at pace, our key initiatives despite the constantly changing backdrop. The Board is confident in the future prospects of the Group and is proposing an increase in the full year dividend of 3%.
“Convatec expects to grow revenue in line or faster than the markets in which we operate, which are growing at approximately 4%. There is still work ahead; however, I am confident in Convatec’s significant growth prospects.”

Group revenue

table

 

Download the full text of this announcement

PDF Download

 

 

Analysts and Investors

ir@convatec.com

Kate Postans: Vice President of Investor Relations & Corporate Communications  

+44 (0)7826 447807

   

Media

 

Buchanan: Charles Ryland / Chris Lane   

+44 (0)207 466 5000

 

Press Release

See all

11/17/2022

Capital Markets Event

Read more

11/10/2022

Trading Update for the 10 months ended 31 October 2022

Read more

8/4/2022

Interim Results for the six months ended 30 June 2022

Read more

5/12/2022

Entry into the attractive wound biologics segment through the acquisition of Triad Life Sciences Inc

Read more

2/28/2022

Non-Executive Directors - Appointment and Resignation

Read more

3/8/2022

Annual Results for the twelve months ended 31 December 2021

Read more

3/14/2022

Convatec Group completes acquisition of Triad Life Sciences Inc as it enters attractive wound biologics segment

Read more

5/13/2022

Convatec invests in BlueWind Medical to fund development of innovative neuromodulation technology

Read more

5/12/2022

AGM trading update for the four months ended 30 April 2022

Read more

1/27/2022

Board committee changes

Read more

5/18/2022

Convatec makes 'forever caring' promise to patients and healthcare providers

Read more